Clinical trials in Boadilla Del Monte – page 101

3 267 clinical trials in Boadilla Del Monte, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Boadilla Del Monte at a glance

3 267

clinical trials

Research sites1

Quick filters

3 267 trials in Boadilla Del Monte

Open in trial search

Colorectal adenocarcinoma

Not yet recruiting

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Verastem Inc.

Contact Research Centre

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not yet recruiting

Comparison of rocbrutinib versus pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Comparison of rocbrutinib versus pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pirtobrutinib
Sponsor:Newave Pharmaceutical Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Phase 1/2 Study of VRN110755 to Assess Safety, Dose and Efficacy in Patients with EGFR‑mutant Non‑Small Cell Lung Cancer

InvestigationalNo placebo

Phase 1/2 Study of VRN110755 to Assess Safety, Dose and Efficacy in Patients with EGFR‑mutant Non‑Small Cell Lung Cancer

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:Voronoi Inc.

Contact Research Centre

Phelan-McDermid syndrome

Not yet recruiting

Study of the Safety, Tolerability and Efficacy of Oral Vafidemstat in Adults with Phelan‑McDermid Syndrome (HOPE‑2)

InvestigationalNo placebo

Study of the Safety, Tolerability and Efficacy of Oral Vafidemstat in Adults with Phelan‑McDermid Syndrome (HOPE‑2)

InvestigationalNo placebo

Spain

Participants:18–64 years
Substances:Vafidemstat
Sponsor:Oryzon Genomics S.A.

Contact Research Centre

Gastric cancer

Not yet recruiting

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Vall D Hebron Institute Of Oncology

Contact Research Centre

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug

Spain

Participants:18–64 years
Substances:Cannabidiol
Sponsor:University Of Oxford

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Graft versus host disease

Not yet recruiting

Study of mesenchymal stromal cells expressing CXCR4 and IL-10 for patients with acute Graft Versus Host Disease who do not respond to steroids or ruxolitinib

InvestigationalNo placebo

Study of mesenchymal stromal cells expressing CXCR4 and IL-10 for patients with acute Graft Versus Host Disease who do not respond to steroids or ruxolitinib

InvestigationalNo placebo

Spain

Participants:18–64 years
Substances:CXCR4/IL10-MSCs
Sponsor:Fundacion Instituto De Investigacion Sanitaria De Navarra

Contact Research Centre

Soft tissue sarcoma

Not yet recruiting

Study of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma

Registered drugNo placebo

Study of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Contact Research Centre

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Contact Research Centre

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin
Sponsor:CSL Behring LLC

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Boadilla Del Monte

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development and immune responses for multiple infectious diseases, including studies of combination vaccines for childhood diseases and COVID-19 boosters.

MMRV Vaccine Studies
COVID-19 Booster Research
RSV Prevention

Special emphasis on pediatric populations and vaccine co-administration safety protocols.

02 Oncology Research

Comprehensive studies on various cancer types, with focus on pediatric liver cancers and innovative treatment approaches for solid tumors.

Hepatoblastoma Treatment
High-Grade Glioma Therapy
Prostate Cancer Management

Integration of targeted therapies and combination treatment protocols.

03 Cardiovascular Medicine

Investigations into cardiovascular disease prevention and treatment, particularly focusing on post-heart attack care and preventive measures.

ASCVD Prevention
Acute Coronary Syndrome
Cardiovascular Risk Management

Emphasis on long-term cardiovascular outcomes and preventive strategies.

04 Women's Health

Studies examining reproductive health and related conditions, including contraceptive efficacy and treatments for gynecological infections.

Contraceptive Development
Vaginal Health Studies
Treatment of Candidiasis

Focus on innovative delivery systems and treatment options.

Back to Spain All countries